Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHIP-AML22 Quizartinib sub-study in pediatric FLT3-ITD positive AML
2023-505000-27-01Phase 2Authorised
- Sponsor
- Princess Máxima Center for Pediatric Oncology
- Start
- Dec 2023
- Modality
- Small Molecules
- Countries
- 14
01
Overview
Phase 2, open-label, single-arm trial of quizartinib in acute myeloid leukemia (AML), sponsored by Princess Máxima Center for Pediatric Oncology. Primary endpoints: MRD negativity after induction and Dose-limiting toxicities. Planned start Dec 2023; status: authorised.
02
Drugs
quizartinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2023-505000-27-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505000-27-01.